SciSparc Ltd.
(NASDAQ : SPRC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.26%177.680.7%$1347.08m
MRKMerck & Co., Inc. 0.44%93.050.7%$1217.31m
PFEPfizer Inc. 0.48%51.890.9%$1100.48m
LLYEli Lilly & Co. 0.25%328.001.1%$1028.73m
BMYBristol-Myers Squibb Co. 0.38%76.251.0%$995.29m
ABBVAbbVie, Inc. -0.97%152.431.9%$950.87m
AZNAstraZeneca Plc 0.40%65.771.0%$472.83m
SGENSeagen Inc. -0.64%175.645.7%$323.98m
GSKGSK Plc -0.75%42.980.2%$270.38m
TPTXTurning Point Therapeutics, Inc. -0.20%75.000.0%$198.88m
HZNPHorizon Therapeutics Plc -1.33%81.665.4%$171.77m
NVSNovartis AG -1.12%83.340.2%$170.34m
ALNYAlnylam Pharmaceuticals, Inc. -0.07%150.638.1%$150.21m
MRTXMirati Therapeutics, Inc. -1.45%70.921.6%$148.63m
NVONovo Nordisk A/S -0.82%110.330.1%$147.15m

Company Profile

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.